Switching from Zepbound to Wegovy

There is no official playbook for switching between these two weight-loss medications. Understanding why people switch, what the evidence does and doesn't show, and how to work with your prescriber will help you go into that conversation prepared.

Most switches between these medications have nothing to do with one drug being better than the other. Insurance and coverage changes are among the most common drivers. Health plans adjust their formularies from year to year, and sometimes mid-year. Prior authorization criteria shift. Cost-sharing structures differ. A plan that covered Zepbound last year may not cover it this year, or may now require steps that weren't previously required. Coverage decisions are unpredictable and vary by plan, so a switch driven by insurance may not be permanent. Tolerability is another reason. Both medications share a class of side effects, primarily gastrointestinal, but individual experiences differ. Someone who struggled with nausea or other GI symptoms on Zepbound may be switching to see whether Wegovy sits better, or vice versa. Access and supply can also play a role. Pharmacy availability, regional supply fluctuations, and other logistical factors sometimes make one medication more accessible than the other at a given time. Patient or prescriber preference may factor in as well: familiarity with a particular injection device, dosing schedule, or other individual considerations.

Understanding the basic difference between these two drugs helps explain why switching between them isn't as simple as swapping one for the other. Wegovy (semaglutide) is a GLP-1 receptor agonist. It works by activating receptors for a hormone called glucagon-like peptide-1, which plays a role in appetite regulation, insulin secretion, and how quickly the stomach empties. Zepbound (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It activates receptors for two hormones — GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) — engaging a somewhat different set of biological pathways. Because these medications act on different receptors to different degrees, the body's response to switching from one to the other isn't straightforward to predict. There is no established dose-equivalence between them, no conversion chart that says a given dose of tirzepatide equals a given dose of semaglutide. This is why the transition requires clinical judgment rather than a simple formula, and why the evidence gap described in the next section has real practical consequences.

The honest answer is that the evidence is thin. No clinical trials have specifically studied the transition from tirzepatide to semaglutide. The prescribing information for both Zepbound and Wegovy does not address switching guidance. No manufacturer has published a recommended protocol for this transition, and no clinical consensus has been established. What does exist is clinical experience: prescribers who have managed patients through this transition and developed their own approaches based on general principles of GLP-1 therapy and individual patient knowledge. That experience is real and valuable, but it is not the same as evidence from controlled studies. The practical implications of this gap are significant. Weight trajectory during and after the switch cannot be reliably predicted; some people maintain their weight, others see fluctuation, and individual response varies considerably. Side effect experience may change, but not in a predictable direction — what you tolerated or didn't tolerate on Zepbound doesn't fully predict what you'll experience on Wegovy. And the long-term outcomes of switching between these medications are simply unknown. This uncertainty is worth naming clearly so that expectations going in are realistic, and so it's clear why your prescriber's judgment, applied to your specific history, is the most important tool available right now.

Without a standard protocol, prescribers rely on clinical reasoning and individual patient knowledge. The following describes how that typically plays out — not as a recommendation, but as context for what you might hear from your own care team.

Dose selection at initiation

Because no conversion ratio exists between tirzepatide and semaglutide, prescribers make a judgment call about where to start. Many choose a conservative starting dose of Wegovy regardless of what dose of Zepbound the patient was taking. The reasoning is generally that it's safer to titrate up than to risk significant side effects from starting too high on a medication the patient hasn't taken before.

Timing of the switch

Whether to begin Wegovy at the next scheduled injection date or allow some gap between the last Zepbound dose and the first Wegovy dose is a clinical judgment call. No washout period has been established as necessary or standard. Your prescriber will make this determination based on your individual circumstances.

Titration pace

Standard Wegovy titration schedules involve starting at a lower dose and increasing gradually over time. These may be followed as written, adjusted, or in some cases moved through more quickly based on a patient's history of tolerability. This, too, is an individualized decision.

Formal monitoring parameters for this specific transition haven't been established, but there are things worth tracking and reporting to your care team.

Weight changes

Expect some variability during the transition period. Tracking your weight consistently — same time of day, same conditions — gives you and your prescriber useful information.

GI symptoms

Nausea, vomiting, diarrhea, and constipation are the most common side effects in this drug class. These may differ in character or intensity from what you experienced on Zepbound. Report anything that feels severe or that interferes with eating, drinking, or daily functioning.

Appetite and satiety signals

Hunger and fullness may feel different on Wegovy than they did on Zepbound. This isn't necessarily a sign that something is wrong, but it's worth noting and discussing with your prescriber.

Injection site reactions

The devices and formulations differ between the two medications. Some people notice differences in injection site comfort or local reactions.

Blood sugar, if applicable

If you have type 2 diabetes or prediabetes, blood sugar monitoring during the transition is particularly important. Ask your prescriber whether any adjustments to your monitoring frequency or other diabetes medications are warranted.

Mood and energy

Some people report shifts in mood or energy levels during medication transitions. This is anecdotal and not well-studied, but worth tracking and mentioning to your care team if you notice it.

When in doubt, report it. Your prescriber would rather hear about something that turns out to be minor than miss something that matters.

Going into your appointment with specific questions helps you get more out of the conversation. Here are questions worth raising:

Why is this switch being recommended, and is it likely to be temporary or permanent? Understanding the reason helps you know what to expect and whether you might return to Zepbound in the future.

What Wegovy dose will I start on, and what's the reasoning? Ask your prescriber to walk you through their thinking.

How closely will my weight and symptoms be monitored during the transition? Understand what follow-up looks like — appointments, check-ins, lab work.

What side effects should prompt me to call the office right away, versus what can I wait and monitor? Get clear guidance on when to reach out.

If I don't respond well to Wegovy, what are the next steps? Know the plan before you need it.

How will we define whether the switch is working? Ask your prescriber to name the milestones they'll be looking for and the timeframe for evaluating them.

Are there aspects of my health history — metabolic complications, GI history, other medications — that should shape how we approach this? Make sure your full picture is part of the conversation.

Obesity treatment is meant to be individualized and managed over the long term. This conversation is part of that ongoing process.

No head-to-head switching studies exist for tirzepatide to semaglutide. No manufacturer has published transition guidance. Predictions about effectiveness, tolerability, or weight outcomes after switching are not reliably supported by evidence, regardless of how confidently they may be stated online. This doesn't mean the switch can't be managed well. It means your prescriber is working with clinical judgment and experience rather than a defined protocol, and that honest, ongoing communication between you and your care team is especially important during this period.

Switching from Zepbound to Wegovy happens in clinical practice, but without a standardized protocol to guide it.

No clinical trials, manufacturer guidance, or established clinical consensus exists for this specific transition.

Your prescriber will make individualized decisions about dose and timing based on your history and their clinical judgment.

Tracking your symptoms and weight during the transition, and communicating proactively with your care team, is the most actionable thing you can do.